eIF3f reduces tumor growth by directly interrupting clusterin with anti-apoptotic property in cancer cells

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Secretory clusterin (sCLU) overexpression promotes cancer cell proliferation and reduces chemosensitivity.
• sCLU is a potential therapeutic target for anticancer strategies.

Purpose of the Study:

• To identify novel proteins interacting with clusterin (CLU).
• To investigate the inhibitory function of eIF3f on sCLU.
• To explore the therapeutic potential of eIF3f in cancer treatment.

Main Methods:

• Protein-protein interaction assays to identify CLU-binding partners.
• Overexpression studies of eIF3f in cancer cell lines.
• Western blotting and signaling pathway analysis (Akt, ERK, p53).
• In vivo xenograft models to assess tumor growth inhibition.

Main Results:

• eIF3f was identified as a novel CLU-interacting protein and functions as a CLU inhibitor.
• eIF3f overexpression significantly retarded cancer cell growth, induced apoptosis, and suppressed Akt/ERK signaling.
• eIF3f stabilized p53, increasing p21 and Bax expression, and inhibited tumor growth in a xenograft model.

Conclusions:

• eIF3f acts as a novel inhibitor of secretory clusterin (sCLU).
• eIF3f demonstrates significant anticancer effects by inhibiting cancer cell proliferation, inducing apoptosis, and suppressing tumor growth.
• Targeting eIF3f offers a promising new strategy for CLU-targeted anticancer therapies.